Cortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network
[Skip to Navigation]
Sign In
α7 Nicotinic acetylcholine receptor binding (A and B) and total β-amyloid (Aβ) peptide concentrations (C and D) in the frontal cortex from subjects categorized into clinical diagnostic groups of no cognitive impairment (NCI), mild cognitive impairment (MCI), and Alzheimer disease (AD) (A and C) or into neuropathological groups of not AD and AD (possible, probable, or definite) by modified Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria (B and D). MLA indicates [3H]methyllycaconitine.

α7 Nicotinic acetylcholine receptor binding (A and B) and total β-amyloid (Aβ) peptide concentrations (C and D) in the frontal cortex from subjects categorized into clinical diagnostic groups of no cognitive impairment (NCI), mild cognitive impairment (MCI), and Alzheimer disease (AD) (A and C) or into neuropathological groups of not AD and AD (possible, probable, or definite) by modified Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria (B and D). MLA indicates [3H]methyllycaconitine.

Table 1. 
Demographic, Clinical, and Neuropathological Characteristics by Diagnostic Group
Demographic, Clinical, and Neuropathological Characteristics by Diagnostic Group
Table 2. 
Superior Frontal Cortex MLA Binding and Aβ ELISA Levels by Diagnostic Group
Superior Frontal Cortex MLA Binding and Aβ ELISA Levels by Diagnostic Group
Table 3. 
Association Between Clinical/Neuropathological Variables and Superior Frontal Cortex MLA Binding and Aβ ELISA Levels
Association Between Clinical/Neuropathological Variables and Superior Frontal Cortex MLA Binding and Aβ ELISA Levels
Original Contribution
May 2009

Cortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease

Author Affiliations

Author Affiliations: Departments of Neurology (Drs Ikonomovic, Abrahamson, and DeKosky) and Psychiatry (Drs Ikonomovic and DeKosky), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa (Dr Wecker); Neurostatistics Section, Department of Neurology, Emory University, Atlanta, Georgia (Ms Wuu); Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (Drs Counts and Mufson); and Nathan Kline Institute and Departments of Psychiatry, Physiology, and Neuroscience, New York University School of Medicine, Orangeburg (Dr Ginsberg).

Arch Neurol. 2009;66(5):646-651. doi:10.1001/archneurol.2009.46

Objective  To examine α7 nicotinic acetylcholine receptor (nAChR) binding and β-amyloid (Aβ) peptide load in superior frontal cortex (SFC) across clinical and neuropathological stages of Alzheimer disease (AD).

Design  Quantitative measures of α7 nAChR by [3H]methyllycaconitine binding and Aβ concentration by enzyme-linked immunosorbent assay in SFC were compared across subjects with antemortem clinical classification of no cognitive impairment, mild cognitive impairment, or mild to moderate AD, and with postmortem neuropathological diagnoses.

Setting  Academic medical center.

Subjects  Twenty-nine elderly retired clergy.

Main Outcome Measures  Quantitative measures of α7 nAChR binding and Aβ peptide concentration in SFC.

Results  Higher concentrations of total Aβ peptide in SFC were associated with clinical diagnosis of mild to moderate AD (P = .02), lower Mini-Mental State Examination scores (P = .003), presence of cortical Aβ plaques (P = .02), and likelihood of AD diagnosis by the National Institute on Aging–Reagan criteria (P = .002). Increased α7 nAChR binding was associated with National Institute on Aging–Reagan diagnosis (P = .02) and, albeit weakly, the presence of cortical Aβ plaques (P = .08). There was no correlation between the 2 biochemical measures.

Conclusions  These observations suggest that during the clinical progression from normal cognition to neurodegenerative disease state, total Aβ peptide concentration increases while α7 nAChRs remain relatively stable in SFC. Regardless of subjects' clinical status, however, elevated α7 nAChR binding is associated with increased Aβ plaque pathology, supporting the hypothesis that cellular expression of these receptors may be upregulated selectively in Aβ plaque–burdened brain areas.

Cholinergic synaptic dysfunction contributes to cognitive impairment in Alzheimer disease (AD). These changes may be due, in part, to increased concentrations of β-amyloid (Aβ) peptides1 and their interactions with nicotinic acetylcholine receptors (nAChRs), which are essential for normal cognitive function.2,3 β-amyloid binds to nAChRs, particularly the α7 subclass4,5; this may alter receptor function6-10 and also result in Aβ internalization, fibrillization, and deposition into plaques and cerebral vasculature.4,11-13 The status of α7 nAChRs in AD is controversial as there are reports of increases, decreases, or stability in AD.14-18 While non-α7 nAChR binding in frontal cortex declines early in AD,19 quantitative biochemical studies specific for α7 nAChRs in subjects with preclinical and early AD remain to be performed. The current study quantified α7 nAChR binding and total Aβ peptide concentration in superior frontal cortex (SFC) from subjects who participated in the Religious Orders Study.20,21 The status of these 2 biochemical measures was examined across subjects' groups defined by clinical diagnoses of no cognitive impairment (NCI), mild cognitive impairment (MCI), and early AD stage (mild to moderate AD [mAD]), or neuropathological diagnosis.


This study included 29 participants in the Religious Orders Study, a longitudinal clinical-pathological study of aging and AD in retired Catholic nuns, priests, and brothers.20 Inclusion criteria and a description of the clinical evaluation have been published.20,21 At the last clinical evaluation (<12 months prior to death), subjects were classified as having NCI, MCI, or mAD (Table 1). Diagnosis of AD dementia was made using standard criteria.22 Mild cognitive impairment was defined as impairment on neuropsychological testing but without a diagnosis of dementia by the examining neurologist,20 criteria similar to those describing patients who were not cognitively intact but nonetheless did not meet the criteria for dementia.23-26 A consensus conference of neurologists and neuropsychologists reviewed all the clinical and neuroimaging data, medical records, and interviews with family members and assigned a final diagnosis.

Neuropathological evaluation

Neuropathological diagnosis of AD (possible, probable, or definite AD) or not AD (Table 1) was based on modified criteria by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD),27 which applied semiquantitative estimates of neuritic plaque density by a board-certified neuropathologist blinded to the clinical diagnosis.28 Subjects were also assigned a National Institute on Aging (NIA)–Reagan neuropathological diagnosis29 and a Braak score based on the presence of neurofibrillary tangles.30 Subjects with pathology other than AD were excluded from the study.


Fresh frozen SFC (Brodmann area 9) gray matter was divided into aliquots for nAChR binding and Aβ peptide enzyme-linked immunosorbent assay (ELISA). For α7 nAChR binding, samples were homogenized in 10 volumes of 50mM Tris-hydrochloride (Tris-HCl) buffer (pH = 7.0), centrifuged twice at 40 000 × g for 10 minutes, resuspended in Tris buffer, and stored at −80°C. Samples were thawed and resuspended in an equal volume of Tris buffer containing 0.1% bovine serum albumin.31,32 Samples, 0.5 mg of protein each, were combined with 9.5nM [3H]methyllycaconitine (MLA) (159.1×1010 Bq/mmol; Tocris Cookson Ltd, Bristol, England) in Tris-HCl buffer containing 0.1% bovine serum albumin. Nonspecific binding was measured in the presence of 1mM nicotine. After a 2-hour incubation on ice, bound ligand was separated from free ligand using Whatman GF/B filters (Whatman, Florham Park, New Jersey), presoaked in 0.3% polyethyleneimine. Filters were rinsed with Tris-HCl buffer, placed in scintillation vials, and shaken in scintillation fluid for 1 hour before radioactivity was determined. Specific binding was calculated as the difference between total and nonspecific binding. Results were expressed as femtomoles per milligram of protein.


The Aβ assay was performed using a previously reported protocol.33 Frozen SFC samples were homogenized (150 mg of tissue wet weight/mL of phosphate-buffered saline, pH = 7.4) and 30 mg of homogenized tissue were sonicated in 70% formic acid and centrifuged at 109 000 × g at 4°C for 1 hour, resulting in samples containing both soluble and formic acid–extracted insoluble Aβ peptides. The supernatant was neutralized with 1M Tris and 0.5M sodium phosphate, and the samples were assayed using a fluorescent-based ELISA (BioSource, Carlsbad, California) following the kit's instructions, with a capture antibody specific for the amino terminus of Aβ (amino acids 1-16) and detection antibodies specific for Aβ40 and Aβ42 peptides. Values were determined from standard curves using synthetic Aβ1-40 and Aβ1-42 peptides (BioSource) and expressed as picomoles per gram of wet brain tissue. “Total” Aβ values represent a sum of Aβ1-40 and Aβ1-42 peptide values.

Statistical analysis

β-amyloid levels were log-transformed because of data skewness. Comparisons of demographic characteristics, MLA binding, and Aβ levels between clinically or neuropathologically defined groups were performed using the Wilcoxon rank sum test, Kruskal-Wallis test, or the Fisher exact test, as appropriate. The association between demographic characteristics and MLA binding or Aβ levels was assessed by Spearman rank correlation or Wilcoxon rank sum test. Partial correlation was used for additional analyses adjusting for age. The correlation between MLA binding and Aβ levels was assessed by Spearman correlation. The level of statistical significance was set at .05 (2-sided).

Clinical and pathological analyses

The 3 clinical groups differed in Mini-Mental State Examination (MMSE) scores (P < .001), with the mAD group performing worse than both the NCI and MCI groups (Table 1). Clinical diagnostic groups also differed in CERAD diagnosis (P = .04), Braak staging (P = .04), and the NIA-Reagan diagnosis (P = .02), with the mAD subjects being more advanced neuropathologically compared with both the MCI and NCI groups (Table 1).

Subjects with a CERAD diagnosis of AD (CERAD score < 4; possible, probable, or definite AD; positive for cortical plaques) had lower MMSE scores (P = .06) and more advanced Braak stages and NIA-Reagan neuropathologic diagnoses (P = .004 and P < .001) (Table 1) than the not AD group (CERAD score = 4; no cortical plaques).


The MLA binding levels were slightly higher in mAD subjects; however, the difference was not statistically significant (Table 2). Clinical groups differed in total Aβ (combined Aβ42 and Aβ40; P = .02) (Figure) and Aβ42 (P = .02), but not Aβ40, concentrations, with mAD subjects having the highest levels.

Subjects with a CERAD diagnosis of AD had higher MLA binding (P = .08) (Figure) and higher concentrations of Aβ42 (P = .02), Aβ40 (P = .06), and total Aβ (P = .02) (Table 2) (Figure) in SFC when compared with those with a CERAD diagnosis of not AD.


There was no association of MLA binding with any of the demographic or clinical variables examined. Higher MLA binding levels correlated with greater likelihood of AD by the NIA-Reagan diagnosis (r = −0.47; P = .02) (Table 3) and weakly with Braak staging. There was an association of higher Aβ concentrations with more advanced age (r = 0.48-0.56; P = .01-.03; Table 3), but not with sex, education, the presence of APOE ε4 allele, or postmortem interval. Higher concentrations of total Aβ and Aβ42, but not Aβ40, correlated with lower MMSE scores (r = −0.62 for both; P = .003 and .004) (Table 3). In addition, higher total Aβ and Aβ42 concentrations correlated with worse neuropathological scores (r = 0.62-0.70; P < .01), as did Aβ40 concentrations, although to a lesser extent (Table 3). Adjusting for age, partial correlation showed similar results, although it yielded smaller correlation coefficients. There was no correlation between MLA binding and Aβ protein concentrations.


This study examined SFC α7 nAChR binding and Aβ peptide concentrations across the clinical and neuropathological categories of AD. Both markers were assayed in the same samples of cortical tissue from subjects who were clinically characterized within 12 months before death and neuropathologically evaluated post mortem. We did not detect significant changes in SFC α7 nAChR binding across clinical diagnostic groups. However, a trend toward elevated α7 nAChR binding levels was evident in subjects with CERAD diagnoses of AD (possible, probable, or definite) relative to not AD subjects (without neuritic Aβ plaques). Total Aβ (sum of Aβ42 and Aβ40) and Aβ42 concentrations were elevated in the CERAD-AD group compared with the CERAD–not AD group, as well as in the clinical mAD compared with the MCI and NCI groups. The increase in α7 nAChRs in Aβ plaque–positive subjects, despite the lack of an association with Aβ concentrations, indicates that cellular expression of this receptor is influenced, either directly or indirectly, by the presence of senile plaques. This is in agreement with previous studies in patients with AD and animal models34,35 and is supported further by the current observation that the correlation between α7 nAChR levels and neuropathological staging was stronger using NIA-Reagan criteria compared with Braak staging, the latter relying only on neurofibrillary tangles for stage designation.30

The apparent stability of α7 nAChRs across clinical categories of NCI, MCI, and mAD, and the lack of an association with MMSE scores, could be explained by the presence of plaques in all clinical groups. Cortical plaques were present in more than half of our NCI cases (Table 1), in agreement with previous reports of a substantial AD pathology in cognitively normal aged individuals.28,36-40 Although these studies would benefit from examining larger numbers of cognitively intact subjects free of any Aβ pathology, such individuals are rare, as Aβ plaques are a common feature in brains of elderly individuals.36,37,39,40 Furthermore, the pathological burden of Aβ includes not only insoluble fibrils in plaques, but also soluble Aβ oligomers.41 The impact of these distinct pools of Aβ on α7 nAChR binding in preclinical, early/moderate, and severe end-stage AD cases will be an important question to answer in future studies.

There are several possible explanations for the observed association between Aβ plaques and increased α7 nAChR binding. Plaques may serve as reservoirs of soluble Aβ species,1 which can bind with high affinity to neuronal α7 receptors4,5 into a complex that is subsequently internalized.12 This may result in a compensatory increase in expression of α7 nAChR on the cell surface. Additionally, excessive intracellular accumulation of Aβ42 and subsequent neuronal lysis may contribute to plaque pathology,12 potentially creating a cycle of neuronal degeneration and Aβ plaque deposition in AD. High concentrations of fibrillar Aβ in plaques, or soluble Aβ in the vicinity of these structures, may also influence the upregulation of α7 nAChR by reactive astrocytes. Astrocytes proliferate and display increased α7 nAChR density in the presence of Aβ plaques35,42,43 and upregulate nAChR messenger RNA expression and protein levels when exposed to Aβ in vitro.44 Receptor binding assays cannot differentiate the relative contribution of different cell types to the overall regional expression of α7 nAChRs detected in tissue homogenates. Adding to this complexity are the postsynaptic and presynaptic sites of expression of α7 nAChRs, involving both local neuronal circuitry and afferent projections from distant neuronal cell populations. In this regard, a recent single-cell expression profiling study demonstrated upregulation of α7 nAChR messenger RNA in cortical-projecting basal forebrain cholinergic neurons in mAD subjects,45 suggesting that changes in cortical α7 protein levels involve presynaptic elements on an important cholinergic afferent system. Collectively, these studies suggest that in SFC, α7 nAChR levels reported herein reflect changes both in cortical-projecting cholinergic basal forebrain neurons and regional cell-specific expression of these receptors in response to Aβ pathology.

In conclusion, the present findings demonstrate that cognitive decline in mAD is not associated with detectable changes in cortical α7 nAChR binding levels. In contrast, Aβ concentrations increased in mAD and correlated with cognitive impairment, in accord with reported associations of increased Aβ load with cognitive decline in AD.46,47 The observed trend for increased SFC α7 in subjects with plaques is in agreement with a previously reported positive correlation between α-bungarotoxin binding and Aβ plaque density34 and warrants further investigation. These changes are in contrast with reports of reduced cortical α4 nAChR immunoreactivity with increased Aβ plaque densities and a loss of epibatidine binding with increased Aβ42 concentrations.34 Thus, α7 and non-α7 nAChRs may be differentially affected by Aβ pathology. In vivo positron emission tomography imaging techniques using radiolabeled probes for early detection of Aβ plaques48,49 and changes in select nAChRs50 may act as early biomarkers for AD and will enable the timely implementation of appropriate therapies.

Correspondence: Steven T. DeKosky, MD, University of Virginia School of Medicine, PO Box 800793, Charlottesville, VA 22908 (

Accepted for Publication: November 5, 2008.

Author Contributions:Study concept and design: Ikonomovic, Wecker, Abrahamson, Ginsberg, Mufson, and DeKosky. Acquisition of data: Ikonomovic, Wecker, and DeKosky. Analysis and interpretation of data: Ikonomovic, Wecker, Abrahamson, Wuu, Counts, Ginsberg, Mufson, and DeKosky. Drafting of the manuscript: Ikonomovic, Wecker, Abrahamson, Wuu, and Mufson. Critical revision of the manuscript for important intellectual content: Ikonomovic, Wecker, Abrahamson, Wuu, Counts, Ginsberg, Mufson, and DeKosky. Statistical analysis: Wuu. Obtained funding: Ikonomovic, Ginsberg, Mufson, and DeKosky. Administrative, technical, and material support: Ikonomovic, Wecker, Ginsberg, and DeKosky. Study supervision: Ikonomovic.

Financial Disclosure: None reported.

Funding/Support: This work was supported by NIA grants AG14449 and AG10610.

Additional Contributions: Theresa Landers-Concatelli, MS, and William R. Paljug, MS, provided expert technical assistance. We are indebted to the support of the participants in the Religious Orders Study; for a list of participating groups, see

Haass  CSelkoe  DJ Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.  Nat Rev Mol Cell Biol 2007;8 (2) 101- 112PubMedGoogle ScholarCrossref
Newhouse  PAPotter  PCorwin  JLenox  R Acute nicotinic blockade produces cognitive impairment in normal humans.  Psychopharmacology (Berl) 1992;108 (4) 480- 484PubMedGoogle ScholarCrossref
Kadir  AAlmkvist  OWall  ALångström  BNordberg  A PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease.  Psychopharmacology (Berl) 2006;188 (4) 509- 520PubMedGoogle ScholarCrossref
Wang  H-YLee  DHSD'Andrea  MRPeterson  PAShank  RPReitz  AB Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology.  J Biol Chem 2000;275 (8) 5626- 5632PubMedGoogle ScholarCrossref
Wang  H-YLee  DHSDavis  CBShank  P Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors.  J Neurochem 2000;75 (3) 1155- 1161PubMedGoogle ScholarCrossref
Pettit  DLShao  ZYakel  JL Beta-amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice.  J Neurosci 2001;21 (1) RC120PubMedGoogle Scholar
Liu  QKawai  HBerg  DK Beta-amyloid peptide blocks the response of alpha7-containing nicotinic receptors on hippocampal neurons.  Proc Natl Acad Sci U S A 2001;98 (8) 4734- 4739PubMedGoogle ScholarCrossref
Dineley  KTWesterman  MBui  DBell  KAshe  KHSweatt  JD Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease.  J Neurosci 2001;21 (12) 4125- 4133PubMedGoogle Scholar
Dineley  KTBell  KBui  DSweatt  JD Beta-amyloid peptide activates alpha7 nicotinic acetylcholine receptors expressed in Xenopus oocytes.  J Biol Chem 2002;277 (28) 25056- 25061PubMedGoogle ScholarCrossref
Dougherty  JJWu  JNichols  RA Beta-amyloid regulation of presynaptic nicotinic receptors in rat hippocampus and neocortex.  J Neurosci 2003;23 (17) 6740- 6747PubMedGoogle Scholar
D'Andrea  MRNagele  RGWang  HYPeterson  PALee  DH Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease.  Histopathology 2001;38 (2) 120- 134PubMedGoogle ScholarCrossref
Nagele  RGD'Andrea  MRAnderson  WJWang  HY Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha7 nicotinic acetylcholine receptor in Alzheimer's disease.  Neuroscience 2002;110 (2) 199- 211PubMedGoogle ScholarCrossref
Clifford  PMSiu  GKosciuk  M  et al.  Alpha7 nicotinic acetylcholine receptor expression by vascular smooth muscle cells facilitates the deposition of Abeta peptides and promotes cerebrovascular amyloid angiopathy.  Brain Res 2008;1234158- 171PubMedGoogle ScholarCrossref
Martin-Ruiz  CMCourt  JAMolnar  E  et al.  Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease.  J Neurochem 1999;73 (4) 1635- 1640PubMedGoogle ScholarCrossref
Paterson  DNordberg  A Neuronal nicotinic receptors in the human brain.  Prog Neurobiol 2000;61 (1) 75- 111PubMedGoogle ScholarCrossref
Court  JMartin-Ruiz  CMPiggott  MSpurden  DGriffiths  MPerry  E Nicotinic receptor abnormalities in Alzheimer's disease.  Biol Psychiatry 2001;49 (3) 175- 184PubMedGoogle ScholarCrossref
Nordberg  A Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.  Biol Psychiatry 2001;49 (3) 200- 210PubMedGoogle ScholarCrossref
Perry  EKMartin-Ruiz  CMCourt  JA Nicotinic receptor subtypes in human brain related to aging and dementia.  Alcohol 2001;24 (2) 63- 68PubMedGoogle ScholarCrossref
Sabbagh  MNShah  FReid  RT  et al.  Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging.  Arch Neurol 2006;63 (12) 1771- 1776PubMedGoogle ScholarCrossref
Bennett  DAWilson  RSSchneider  JA  et al.  Natural history of mild cognitive impairment in older persons.  Neurology 2002;59 (2) 198- 205PubMedGoogle ScholarCrossref
Mufson  EJCounts  SEChe  SGinsberg  SD Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease.  Prog Brain Res 2006;158197- 222PubMedGoogle Scholar
McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.  Neurology 1984;34 (7) 939- 944PubMedGoogle ScholarCrossref
Albert  MSmith  LASteer  PA  et al.  Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease.  Int J Neurosci 1991;57 (3-4) 167- 178PubMedGoogle ScholarCrossref
Devanand  DPFolz  MGorlyn  MMoeller  JRStern  Y Questionable dementia: clinical course and predictors of outcome.  J Am Geriatr Soc 1997;45 (3) 321- 328PubMedGoogle Scholar
Petersen  RCSmith  GEWaring  SCIvnik  RJTangalos  EGKokmen  E Mild cognitive impairment: clinical characterization and outcome.  Arch Neurol 1999;56 (3) 303- 308PubMedGoogle ScholarCrossref
Morris  JCPrice  AL Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease.  J Mol Neurosci 2001;17 (2) 101- 118PubMedGoogle ScholarCrossref
Mirra  SSHeyman  A McKeel  D  et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), part II: standardization of the neuropathologic assessment of Alzheimer's disease.  Neurology 1991;41 (4) 479- 486PubMedGoogle ScholarCrossref
Bennett  DASchneider  JABienias  JLEvans  DAWilson  RS Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions.  Neurology 2005;64 (5) 834- 841PubMedGoogle ScholarCrossref
The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease, Consensus recommendations for the postmortem diagnosis of Alzheimer's disease.  Neurobiol Aging 1997;18 (4) ((suppl)) S1- S2PubMedGoogle ScholarCrossref
Braak  HBraak  E Neuropathological stageing of Alzheimer-related changes.  Acta Neuropathol 1991;82 (4) 239- 259PubMedGoogle ScholarCrossref
Davies  ARHardick  DJBlagbrough  ISPotter  BVWolstenholme  AJWonnacott  S Characterization of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors.  Neuropharmacology 1999;38 (5) 679- 690PubMedGoogle ScholarCrossref
Ward  JMCockcroft  VBLunt  GGSmillie  FSWonnacott  S Methyllycaconitine: a selective probe for neuronal alpha-bungarotoxin binding sites.  FEBS Lett 1990;270 (1-2) 45- 48PubMedGoogle ScholarCrossref
Ikonomovic  MDKlunk  WEAbrahamson  EE  et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.  Brain 2008;131 (pt 6) 1630- 1645PubMedGoogle ScholarCrossref
Perry  EMartin-Ruiz  CLee  M  et al.  Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases.  Eur J Pharmacol 2000;393 (1-3) 215- 222PubMedGoogle ScholarCrossref
Yu  WFGuan  ZZBogdanovic  NNordberg  A High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques.  Exp Neurol 2005;192 (1) 215- 225PubMedGoogle ScholarCrossref
Mufson  EJChen  EYCochran  EJBeckett  LABennett  DAKordower  JH Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment.  Exp Neurol 1999;158 (2) 469- 490PubMedGoogle ScholarCrossref
Forman  MSMufson  EJLeurgans  S  et al.  Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis.  Neurology 2007;68 (10) 757- 763PubMedGoogle ScholarCrossref
Bennett  DASchneider  JAArvanitakis  Z  et al.  Neuropathology of older persons without cognitive impairment from two community-based studies.  Neurology 2006;66 (12) 1837- 1844PubMedGoogle ScholarCrossref
Markesbery  WRSchmitt  FAKryscio  RJDavis  DGSmith  CDWekstein  DR Neuropathologic substrate of mild cognitive impairment.  Arch Neurol 2006;63 (1) 38- 46PubMedGoogle ScholarCrossref
Petersen  RCParisi  JEDickson  DW  et al.  Neuropathologic features of amnestic mild cognitive impairment.  Arch Neurol 2006;63 (5) 665- 672PubMedGoogle ScholarCrossref
Wang  JDickson  DWTrojanowski  JQLee  V The levels of soluble versus insoluble brain Aß distinguish Alzheimer's disease from normal and pathologic aging.  Exp Neurol 1999;158 (2) 328- 337PubMedGoogle ScholarCrossref
Teaktong  TGraham  ACourt  J  et al.  Alzheimer's disease is associated with a selective increase in alpha 7 nicotinic acetylcholine receptor immunoreactivity in astrocytes.  Glia 2003;41 (2) 207- 211PubMedGoogle ScholarCrossref
Teaktong  TGraham  AJCourt  JA  et al.  Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology.  J Neurol Sci 2004;225 (1-2) 39- 49PubMedGoogle ScholarCrossref
Xiu  JNordberg  AZhang  JTGuan  ZZ Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentration of the beta-amyloid peptide(1-42).  Neurochem Int 2005;47 (4) 281- 290PubMedGoogle ScholarCrossref
Counts  SEHe  BChe  S  et al.  Alpha7 nicotinic receptor up-regulation in cholinergic basal forebrain neurons in Alzheimer disease.  Arch Neurol 2007;64 (12) 1771- 1776PubMedGoogle ScholarCrossref
Cummings  BJPike  CJShankle  RCotman  CW Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.  Neurobiol Aging 1996;17 (6) 921- 933PubMedGoogle ScholarCrossref
Näslund  JHaroutunian  VMohs  R  et al.  Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline.  JAMA 2000;283 (12) 1571- 1577PubMedGoogle ScholarCrossref
Klunk  WELopresti  BJIkonomovic  MD  et al.  Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.  J Neurosci 2005;25 (46) 10598- 10606PubMedGoogle ScholarCrossref
Nordberg  A Amyloid imaging in Alzheimer's disease.  Neuropsychologia 2008;46 (6) 1636- 1641PubMedGoogle ScholarCrossref
Nordberg  A Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. Ezio  GPepeu  G The Brain Cholinergic System. London, England Martin Dunitz2006;Google Scholar